Vitamin D enhances erlotinib response in EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Shaurova, Tatiana
Shoemaker, Suzanne F.
Hershberger, Pamela A.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-4674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4674
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen
    Ichidai Tanaka
    Masahiro Morise
    Junji Koyama
    Yuta Kodama
    Akira Matsui
    Ayako Miyazawa
    Tetsunari Hase
    Yoshitaka Hibino
    Toshihiko Yokoyama
    Tomoki Kimura
    Norio Yoshida
    Mitsuo Sato
    Naozumi Hashimoto
    BMC Cancer, 22
  • [32] Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
    Gao, Wen
    Wang, Michael
    Wang, Li
    Lu, Haibo
    Wu, Shuhong
    Dai, Bingbing
    Ou, Zhishuo
    Zhang, Liang
    Heymach, John V.
    Gold, Kathryn A.
    Minna, John
    Roth, Jack A.
    Hofstetter, Wayne L.
    Swisher, Stephen G.
    Fang, Bingliang
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [33] Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer
    Lantermann, Alexandra B.
    Chen, Dongshu
    McCutcheon, Kaitlin
    Hoffman, Greg
    Frias, Elizabeth
    Ruddy, David
    Rakiec, Daniel
    Korn, Joshua
    McAllister, Gregory
    Stegmeier, Frank
    Meyer, Matthew J.
    Sharma, Sreenath V.
    CANCER RESEARCH, 2015, 75 (22) : 4937 - 4948
  • [34] Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p)
    Karachaliou, Niki
    Drozdowskyj, Ana
    Gimenez Capitan, Ana
    Cardona Zorrilla, Andres Felipe
    Gervais, Radj
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny Costa, Enric
    Garcia Campeio, Rosario
    Viteri Ramirez, Santiago
    Morales-Espinosa, Daniela
    Verlicchi, Alberto
    Crisetti, Elisabetta
    Chaib, Imane
    Luis Ramirez, Jose
    Ma, Patrick C.
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer
    Ahn, Beung-Chul
    Park, Charny
    Kim, Moon Soo
    Lee, Jong Mog
    Choi, Jin Ho
    Kim, Hyae Young
    Lee, Geon Kook
    Yu, Namhee
    Lee, Youngjoo
    Han, Ji-Youn
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 70 - 80
  • [36] Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
    Attili, Ilaria
    Passaro, Antonio
    Corvaja, Carla
    Aliaga, Pamela Trillo
    Del Signore, Ester
    Spitaleri, Gianluca
    de Marinis, Filippo
    CANCER TREATMENT REVIEWS, 2023, 119
  • [37] Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases
    Yang, T. Jonathan
    Wu, Abraham J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 134 - 137
  • [38] OLIMPIA dataset: Radiomics to predict outcomes in EGFR-mutant non-small cell lung cancer
    Perez, G.
    Minatta, J. N.
    Aineseder, M.
    Mosquera, C.
    Benitez, S. E.
    ANNALS OF ONCOLOGY, 2022, 33 : S18 - S18
  • [39] The role of PD-L1 in EGFR-mutant non-small cell lung cancer
    Wentao Gao
    Lingling Wang
    Yanyan Zhao
    Lucheng Zhu
    Discover Oncology, 16 (1)
  • [40] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
12345